Evogene Schedules Second Quarter 2024 Financial Results Release - StockTitan
| EVGN Stock | ILA 602.20 18.60 3.19% |
About 54% of Evogene's investors are presently thinking to get in. The analysis of current outlook of investing in Evogene suggests that some traders are interested regarding Evogene's prospects. The current market sentiment, together with Evogene's historical and current headlines, can help investors time the market. In addition, many technical investors use Evogene stock news signals to limit their universe of possible portfolio assets.
Evogene |
Evogene Schedules Second Quarter 2024 Financial Results Release StockTitan
Read at news.google.com
 |
Evogene Fundamental Analysis
We analyze Evogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Evogene is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Evogene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evogene stock to make a market-neutral strategy. Peer analysis of Evogene could also be used in its relative valuation, which is a method of valuing Evogene by comparing valuation metrics with similar companies.
Peers
Evogene Related Equities
| CGEN | Compugen | 1.57 | ||||
| BLRX | BioLine RX | 1.25 | ||||
| KMDA | Kamada | 0.71 | ||||
| ENLV | Enlivex Therapeutics | 0.98 | ||||
| EVGN | Evogene | 4.73 |
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |